Keloids – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Keloids, resulting from abnormal wound healing triggered by skin trauma or inflammation, are influenced by genetic and environmental factors. They are more prevalent among individuals of African, Asian, and Hispanic descent. Overactive fibroblasts, producing excessive collagen and growth factors, are implicated in their pathogenesis, leading to the characteristic histologic findings of keloidal collagen bundles and numerous fibroblasts. Clinically, keloids manifest as firm, rubbery nodules extending beyond the initial injury site, often accompanied by pain, itching, or burning. The differential diagnosis includes hypertrophic scars, which are smaller and confined to the injury area, and dermatofibroma, characterized by flesh-colored or hyperpigmented papules or nodules. Due to the therapeutic challenges posed by keloids, prevention plays a crucial role. For predisposed individuals, it is recommended to avoid elective procedures, especially ear piercing and tattooing. Minimizing wound tension and employing compression therapy, with 15 to 45 mmHg pressures for over 23 hours daily for at least 6 months, can help reduce keloid formation and growth.
Thelansis’s “Keloids Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Keloids treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Keloids across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Keloids Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment